Siemens Healthineers AG (SMMNY) Stock Price & Analysis
Siemens Healthineers AG (SMMNY) — price $21.29 (+0.95%), as of the Oct 2, 2026 trading session; market cap $23.8B. Expected results Nov 5, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Siemens Healthineers AG · SMMNY · Healthcare · Medical - Devices
Siemens Healthineers AG (SMMNY), operating through its various subsidiaries, is a global enterprise that provides a comprehensive suite of diagnostic and therapeutic medical products and services.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $21.29 | |
| Change on the day | +0.95% | |
| 52-week range | $19.20 – $28.92 | |
| Market capitalisation | $23.8B | |
| Price / earnings (trailing) | 19.12 | |
| Shares traded on the day | 10.3K | |
| Beta (volatility vs the S&P 500) | 0.83 | |
| Dividends per share (last 12 months) | $0.59 | |
| Dividend yield (last 12 months) | 2.79% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
As outlined before, we expect a clear acceleration of revenue growth in the synergetic core with Imaging accelerating into the higher single digits and Precision Therapy continuing growth in the higher single digits, maybe not fully at the 9% level of the current quarter.
Jochen Schmitz · Statement from
In Precision Therapy, year-over-year margin expansion will be tough against the very high prior year quarter of 17%, but we expect a good sequential improvement with the 14% margin ex tariff refunds from Q3 this quarter.
Jochen Schmitz · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Siemens Healthineers AG (SMMNY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 1, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 1, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the SMMNY film — every key number, told as a short cinematic story
~2 min · open the film
What is Siemens Healthineers AG (SMMNY), and what does it report?
Short answer · as of
Siemens Healthineers AG (SMMNY), operating through its various subsidiaries, is a global enterprise that provides a comprehensive suite of diagnostic and therapeutic medical products and services. Healthcare / Medical Devices Headquarters: Siemensstr. 3, Forchheim, BV, 91301, DE. It employs 74,000 people and is led by Bernhard Montag. In Q3 FY2026 it reported revenue of $6.47B and net income of $751M. The market values it at $23.8B.
What do the latest results show for Siemens Healthineers AG (SMMNY)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $6.47B. Against analyst estimates the company has EPS beat 4 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $6.63B Jul 31, 2026
- Latest report · revenue estimate
- $6.45B Jul 31, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 31, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 31, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 31, 2026 | $6.63B | $6.45B | $0.4027 | $0.3022 |
| May 7, 2026 | $6.69B | $6.96B | $0.3121 | $0.2936 |
| Feb 5, 2026 | $6.37B | $6.15B | $0.2889 | $0.2628 |
| Nov 5, 2025 | $5.83B | $6.06B | $0.3075 | $0.3986 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $6.47B | $751M | $0.34 (diluted) |
| Q2 FY2026 | $6.48B | $577M | $0.13 (diluted) |
| Q1 FY2026 | $6.01B | $500M | $0.22 (diluted) |
| Q4 FY2025 | $5.59B | $659M | $0.29 (diluted) |
What are the financial strengths and risks for Siemens Healthineers AG (SMMNY)?
Short answer
The distress and quality screens read Altman Z 1.36 · Piotroski F 8. Trailing ratios: ROE 12.0% · ROA 4.8% · current ratio 1.16 · earnings yield 5.2% · free-cash-flow yield 5.2%.
What should you watch next at Siemens Healthineers AG (SMMNY)?
Short answer · as of
The next earnings report is expected on Nov 5, 2026.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
As outlined before, we expect a clear acceleration of revenue growth in the synergetic core with Imaging accelerating into the higher single digits and Precision Therapy continuing growth in the higher single digits, maybe not fully at the 9% level of the current quarter.
Jochen Schmitz ·
In Precision Therapy, year-over-year margin expansion will be tough against the very high prior year quarter of 17%, but we expect a good sequential improvement with the 14% margin ex tariff refunds from Q3 this quarter.
Jochen Schmitz ·
Consequently, we expect for the full year, the Diagnostic margin ex refunds to approach the full year assumption from below, which is a mid-triple-digit basis points decline.
Jochen Schmitz ·
Hence, we expect revenue to shift from Q3 into Q4.
Jochen Schmitz ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
What has been published about Siemens Healthineers AG (SMMNY)?
- Assessment of the Global Intraoperative Radiation Therapy Market 2026-2031, Featuring Profiles of Siemens Healthineers, Elekta, Carl Zeiss Meditec, IntraOp Medical, iCAD and More
- Cardiovascular Ultrasound Systems Market Outlook 2026-2030 | Projected to Reach $2.77 Billion by 2030 as AI Adoption Accelerates | Featuring Profiles of GE HealthCare, Philips, and Siemens Healthineers
- Delays Before Patients Reach Stroke Centers Still Hinder Timely Treatment Across Southeast Asia, Siemens Healthineers Report Finds
- Siemens Healthineers showcases its AI-powered technological innovations to redefine healthcare delivery in Southeast Asia
Common Questions About SMMNY (Healthcare)
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Varian contribute to Siemens Healthineers?
Varian extends the portfolio into oncology technology, clinical services and operational support for cancer-care departments. It connects Siemens Healthineers to therapy delivery and oncology workflows rather than limiting the business to diagnosis.
Why does shifted revenue matter for Siemens Healthineers?
Management said revenue moved from the reported period into the following period, making subsequent delivery the practical test of that explanation. Failure to recover the shifted business would weaken the expected acceleration in the core portfolio.
What is the SMMNY stock price today?
The last price recorded on this page for Siemens Healthineers AG (SMMNY) is $21.29, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does SMMNY pay a dividend?
Yes. Siemens Healthineers AG (SMMNY) shows a trailing 12-month dividend yield of 2.79%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (42 figures)
The 42 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Jochen Schmitz (Jul 31, 2026): As outlined before, we expect a clear acceleration of revenue growth in the synergetic core with Imaging accelerating into the higher single digits and Precision Therapy continuing growth in the higher single digits, maybe not fully at the 9% level of the current quarter. Jochen Schmitz (Jul 31, 2026): In Precision Therapy, year-over-year margin expansion will be tough against the very high prior year quarter of 17%, but we expect a good sequential improvement with the 14% margin ex tariff refunds from Q3 this quarter. Jochen Schmitz (Jul 31, 2026): Consequently, we expect for the full year, the Diagnostic margin ex refunds to approach the full year assumption from below, which is a mid-triple-digit basis points decline. Jochen Schmitz (Jul 31, 2026): Hence, we expect revenue to shift from Q3 into Q4. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. |
FMP — 32 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $21.29 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T12:34:52.586Z. | |
px.change | Change on the day | +0.95% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $23.8B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-02. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 5, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Siemens Healthineers AG (SMMNY), operating through its various subsidiaries, is a global enterprise that provides a comprehensive suite of diagnostic and therapeutic medical products and services. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$0.20 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 19.12 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 10.3K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.83 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Devices | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Siemensstr. 3, Forchheim, BV, 91301, DE | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 74,000 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Bernhard Montag | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q3 FY2026 | $6.47B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q3 FY2026 | $751M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-07-31.revenue_actual | Revenue · reported — report date 2026-07-31 | $6.63B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-31.revenue_estimated | Revenue · estimate — report date 2026-07-31 | $6.45B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-31.eps_actual | EPS · reported — report date 2026-07-31 | $0.4027 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-31.eps_estimated | EPS · estimate — report date 2026-07-31 | $0.3022 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_actual | Revenue · reported — report date 2026-05-07 | $6.69B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $6.96B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | $0.3121 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | $0.2936 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.revenue_actual | Revenue · reported — report date 2026-02-05 | $6.37B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.revenue_estimated | Revenue · estimate — report date 2026-02-05 | $6.15B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.eps_actual | EPS · reported — report date 2026-02-05 | $0.2889 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.eps_estimated | EPS · estimate — report date 2026-02-05 | $0.2628 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_actual | Revenue · reported — report date 2025-11-05 | $5.83B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_estimated | Revenue · estimate — report date 2025-11-05 | $6.06B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_actual | EPS · reported — report date 2025-11-05 | $0.3075 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_estimated | EPS · estimate — report date 2025-11-05 | $0.3986 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q3 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $19.20 – $28.92 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-03 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 1.36 · Piotroski F 8 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 12.0% · ROA 4.8% · current ratio 1.16 · earnings yield 5.2% · free-cash-flow yield 5.2% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.59 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.79% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-31.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($6.63B) with the recorded estimate ($6.45B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-31.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.4027) with the recorded estimate ($0.3022) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-07-31. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-31.revenue_actual,earn.history.depth.2026-07-31.revenue_estimated,earn.history.depth.2026-07-31.revenue_actual.comparison,earn.history.depth.2026-07-31.eps_actual.comparison,earn.history.depth.2026-07-31.eps_actual,earn.history.depth.2026-07-31.eps_estimated,earn.history.depth.2026-05-07.revenue_actual,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-02-05.revenue_actual,earn.history.depth.2026-02-05.revenue_estimated,earn.history.depth.2026-02-05.eps_actual,earn.history.depth.2026-02-05.eps_estimated,earn.history.depth.2025-11-05.revenue_actual,earn.history.depth.2025-11-05.revenue_estimated,earn.history.depth.2025-11-05.eps_actual,earn.history.depth.2025-11-05.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Siemens Healthineers AG (SMMNY), operating through its various subsidiaries, is a global enterprise that provides a comprehensive suite of diagnostic and therapeutic medical products and services. These offerings are extended to healthcare professionals and institutions across numerous international markets, including Germany, the United States, the broader European continent, the CIS region, Africa, the Middle East, the Americas, the Asia Pacific region, Japan, and China. The company's business is structured across four primary divisions: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment supplies cutting-edge systems such as magnetic resonance imaging (MRI), computed tomography (CT), X-ray, molecular imaging, and ultrasound technologies. It also develops sophisticated software solutions designed to streamline the interpretation and structured reporting of diagnostic images from diverse modalities. The Diagnostics segment delivers in-vitro diagnostic products and associated services, catering to healthcare providers in both general and specialized laboratory settings, as well as point-of-care diagnostics. This division further offers workflow solutions to optimize laboratory operations and provides advanced informatics products. The Varian segment specializes in oncology solutions, featuring advanced technologies like microwave, cryoablation, and embolization. It also furnishes extensive clinical professional services and tailored support programs to assist oncology departments in hospitals and clinics with their cancer care operations. The Advanced Therapies segment focuses on developing products that facilitate image-guided, minimally invasive clinical procedures. These solutions are applied across various medical specialties, including cardiology, neurology, and oncology. Its portfolio includes angiography systems, mobile C-arms, and AI-powered clinical applications that enhance procedural precision. Beyond its core product lines, Siemens Healthineers AG offers a broad range of essential technical customer services. These include maintenance and repair, provision of spare parts, medical equipment performance management, training programs, clinical education, e-learning resources, planning and design assistance, financing options, asset management, and managed departmental services for laboratories and other healthcare facilities. The company also provides healthcare consulting, products, and additional services. Established in 1896, Siemens Healthineers AG maintains its corporate headquarters in Forchheim, Germany, and functions as a subsidiary of Siemens Aktiengesellschaft. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-31 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Next earnings report | Date: 2026-11-05; EPS estimate: $0.3938 per share; Revenue estimate: $7.83B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP) earnings |
Data provided for informational purposes only.
ETFs that hold SMMNY
Funds in our ETF coverage that list SMMNY among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| LGHT ETF | 4.67% |